Navigation Links
Caris Life Sciences Symposium to Explore Advances in Next Generation Sequencing for Gynecologic Cancers
Date:3/8/2013

sights about the genomics of the disease."

The application of NGS technologies holds significant promise in the treatment of ovarian cancer, the most lethal gynecologic cancer in the U.S., resulting in approximately 14,000 deaths annually.1 Although primary ovarian carcinomas initially respond to platinum-based therapy, this response is often incomplete, resulting in relapse in almost 80% of women with advanced disease.2‐4 It's therefore critical to thoroughly assess the entire biology of a tumor using NGS technology, along with more traditional profiling technologies like IHC and FISH.

"Given the high recurrence rate and poor long‐term survival of women with advanced ovarian cancer, there is an urgent need for improved methods of biomarker target identification, chemotherapy selection and clinical trials enrollment," explained Dr. Coleman. "Ovarian neoplasms differ widely with respect to their clinical behavior and response to chemotherapy, suggesting that each patient's disease may harbor unique, clinically actionable molecular targets. When paired with traditional gold-standard pathology, NGS information has the promise to lead to superior therapeutic associations, more rapid and efficient identification of candidates for new clinical trials, and ultimately, better patient management."

In addition to Dr. Coleman, the symposium faculty includes the below experts, whose presentations will address the following topics:

  • NGS Targets in Ovarian Carcinoma: Ryan Bender , Ph.D, FACMG, Director, Molecular Genetics, Caris Life Sciences
  • Integrating NGS Data Into Patient Care – Today: Deborah Zajchowski , Ph.D, Clearity Foundation
  • The Future of Tumor Profiling in Gynecologic Cancers: Maurie Markman , M.D., SVP & National Director of Medical Oncology
    '/>"/>

SOURCE Caris Life Sciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Caris Life Sciences Enhances Molecular Profiling Service with Addition of ROS1 and MGMT-Methylation Biomarkers
2. Caris Life Sciences mejora la evaluación por perfil molecular con los biomarcadores ROS1 y MGMT-metilación
3. Caris Sponsors CancerCare Connect Education Workshop on Molecular Profiling in the Treatment of Breast Cancer
4. Caris Life Sciences Adds Next-Generation Sequencing to Enhance Evidence-Based Tumor Profiling Service for Cancer Patients
5. Caris Life Sciences nimmt Next-Generation Sequencing zur Verbesserung des evidenzbasierten Tumorprofilierungsservices für Krebspatienten auf
6. Garage Start-ups Now Possible in Life Sciences Industry
7. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
8. DiaTech Life Sciences Announces Medical Advisory Board
9. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
10. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
11. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to ... the Lyon County Fair to be held August 5-9 in Marshall. The Ralco Enrichment ... meals come from and how agriculture impacts their daily lives. This unique exhibit also ...
(Date:7/30/2015)... ... , ... The 2015 Market Research Report on the Global Propanol Industry ... Propanol market with a focus on the Chinese situation. Major companies included in the ... Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report ...
(Date:7/30/2015)...   Senomyx , Inc. (NASDAQ: SNMX ), ... discover, develop, and commercialize novel flavor ingredients for the ... results for the second quarter 2015. ... on track to achieve our commercial and financial goals," ... the Company. "Since our last quarterly earnings report, our ...
(Date:7/30/2015)... 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... the second $1.0M tranche under a previously awarded ... valued at up to $3.0 million to support ... as a potential medical countermeasure to mitigate acute ... awarded an initial $1.0 million under this grant ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... DIEGO, Oct. 31 Optimer Pharmaceuticals, Inc. (Nasdaq: ... from fidaxomicin,s North American phase 3 study at the ... America (IDSA) in Philadelphia, PA. , (Logo: ... of the Division of Infectious Diseases, Chair of the ...
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a ... today that the Company will host a conference call ... Thursday, November 5, 2009 to discuss its third quarter ... participate in the call, please dial 800-860-2442 (domestic) or ...
... Pa., Oct. 30 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation (Nasdaq: BJGP ) ("BMP ... , , -- Oppenheimer 20th Annual Healthcare Conference, to ... the Waldorf=Astoria hotel in New York. Management is scheduled, ... 3, and meet with, institutional investors ...
Cached Biology Technology:Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting 2Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting 3Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting 4BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5, 2009 2BMP Sunstone Announces November Investor Conference Participation 2
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... Research and Markets ... the "Capacitive Fingerprint Sensors Patent Landscape" ... date, fingerprint sensing technology is the most reliable ... well developed. This patent landscape focuses on fingerprint ... domain of capacitive fingerprint sensors is closely linked ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... decade, Steve Stice has dedicated his research using embryonic ... degenerative diseases and debilitating injuries. His most recent discovery, ... stem cells, could now aid in national security. ... of Georgia animal science professor and Georgia Research Alliance ...
... CHAMPAIGN, Ill. -- By placing quantum dots on ... University of Illinois have demonstrated enhanced fluorescence intensity ... applications include high-brightness,light-emitting diodes, optical switches and personalized, ... a new way, said Brian Cunningham, a professor ...
... have discovered that a specific mutation of the COX2 ... of ovarian cancer, increasing womens susceptibility to developing the ... the findings are confirmed by further studies, it might ... as aspirin and ibuprofen, which are used already for ...
Cached Biology News:New use for stem cells found in war on terrorism 2New use for stem cells found in war on terrorism 3Researchers set new record for brightness of quantum dots 2Mutation of the COX2 gene can double or treble a woman's risk of ovarian cancer 2Mutation of the COX2 gene can double or treble a woman's risk of ovarian cancer 3
...
... PCR Spots, Oligo Spots and complementary RNA ... microarray experiments. Use for glass array printing ... for reverse transcription, cDNA labeling, hybridization stringency ... Control PCR Spots and Oligo Spots, ...
MOUSE ANTI DUCK IgY LIGHT CHAIN...
MOUSE ANTI S. MUTANS PEPTIDOGLYCAN...
Biology Products: